Clearside Biomedical - Stock Price History | CLSD

Historical daily share price chart and data for Clearside Biomedical since 2021 adjusted for splits. The latest closing stock price for Clearside Biomedical as of October 27, 2021 is 5.26.
  • The all-time high Clearside Biomedical stock closing price was 24.72 on October 11, 2016.
  • The Clearside Biomedical 52-week high stock price is 7.73, which is 47% above the current share price.
  • The Clearside Biomedical 52-week low stock price is 1.25, which is 76.2% below the current share price.
  • The average Clearside Biomedical stock price for the last 52 weeks is 3.82.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Clearside Biomedical Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 1.9661 2.1100 3.7700 1.3200 2.7400 -5.52%
2019 1.2160 1.1500 3.4000 0.5858 2.9000 171.03%
2018 7.6136 7.1900 14.5400 1.0000 1.0700 -84.71%
2017 7.7930 9.3700 10.1600 5.7800 7.0000 -21.70%
2016 11.6452 7.2500 24.7200 6.0050 8.9400 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.313B $0.008B
Clearside Biomedical, Inc. is a biopharmaceutical company is engaged in developing first-in-class drug therapies to treat blinding diseases of the eye using Clearside proprietary suprachoroidal space(TM) microinjector. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related macular degeneration. Clearside Biomedical, Inc. is headquartered in Alpharetta, Georgia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86